Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Lung Neoplasms 2Tumor Virus Infections 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Osteosarcoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1Glioblastoma 1Fallopian Tube Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Pancreatic Ductal 1

Interventions

Docetaxel 8pembrolizumab 7Pemetrexed 5Carboplatin 5Erlotinib Hydrochloride 4toripalimab 3rociletinib 3fludarabine 3Radiosurgery 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Gemcitabine 3Etoposide 3Cyclophosphamide 3Cisplatin 3Bevacizumab 3lorlatinib 2atezolizumab 2Vinorelbine 2Topotecan 2Radiotherapy 2Platinum 2Itraconazole 2Irinotecan 2Interleukin-2 2Cetuximab 2Albumin-Bound Paclitaxel 2vinflunine 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × cc-486 × Thoracic × Clear all
NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Celgene

Phase 1 Completed
169 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡